The nicotine as drug;La nicotina como droga

Adicciones

Volumn 16, Issue SUPPL. 2, 2004, Pages 143-153

  Jiménez Treviño, Luis ^a   Bascarán Fernández, Ma Teresa ^a   García Portilla González, Ma Paz ^a   Sáiz Martínez, Pilar Alejandra ^a   Bousoño García, Manuel ^a   Bobes García, Julio ^a,b  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b Facultad de Medicina   (Spain)

Author keywords

Addiction; Cigarette; Drug; Nicotine

Indexed keywords

NICOTINE;

ADDICTION; CIGARETTE SMOKING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG MECHANISM; HUMAN; MEDICAL SOCIETY; REVIEW; SUBSTANCE ABUSE; WORLD HEALTH ORGANIZATION;

EID: 3242667217     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Lorenzo P, Ladero JM. Dependencia Tabá-quica. Tabaco y nicotina. In: Lorenzo P, Ladero JM, Leza JC, Lizasoain I, editors. Drogodependencias. Madrid: Editorial Médica Panamericana, 2003: 441-457
2. Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 1999; 56(2):99-107
3. Vleeming W, Rambali B, Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob Res 2002; 4(3):341-348.
4. Shytle RD, Silver AA, Sanberg PR. Nicotine, tobacco and addiction. Nature 1996; 384(6604):18-19.
5. Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 1999; 56(2):99-107.
6. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997; 280(3):1117-1136.
7. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70(4):439-446.
8. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991; 350(6315):235-238.
9. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991; 350(6315):235-238.
10. Dani JA, Radcliffe KA, Pidoplichko VI. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 2000; 393(1-3):31-38.
11. Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, Lester RA. Desensitization of nicotinic receptors in the central nervous system. Ann N Y Acad Sci 1999; 868:620-623.
12. Buisson B, Bertrand D. Allosteric modulation of neuronal nicotinic acetylcholine receptors. J Physiol Paris 1998; 92(2):89-100.
13. Changeux JP, Bertrand D, Corringer PJ, Dehaene S, Edelstein S, Lena C et al. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res Brain Res Rev 1998; 26(2-3):198-216.
14. Margiotta JF, Berg DK, Dionne VE. The properties and regulation of functional acetylcholine receptors on chick ciliary ganglion neurons. J Neurosci 1987; 7(11):3612-3622.
15. Lester RA, Dani JA. Time-dependent changes in central nicotinic acetylcholine channel kinetics in excised patches. Neuropharmacology 1994; 33(1):27-34.
16. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390(6658):401-404.
17. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997; 62(4):453-463.
18. Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 1999; 56(2):99-107.
19. Balfour DJ, Benwell ME, Birrell CE, Kelly RJ, Al Aloul M. Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol Biochem Behav 1998; 59(4):1021-1030.
20. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999; 375(1-3):13-30.
21. Bobes J, Casas M, Gutiérrez M. Manual de evaluación y tratamiento de drogodependencias. Barcelona: Psiquiatría Editores, 2003.
22. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 1986; 30(5):427-436.
23. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390(6658):401-404.
24. Dani JA, Radcliffe KA, Pidoplichko VI. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 2000; 393(1-3):31-38.
25. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 1986; 30(5):427-436.
26. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol ExpTher 1999; 289(3):1545-1552.
27. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K et al. Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 1998; 273(44):28721-28732.
28. Russell MA. Subjective and behavioural effects of nicotine in humans: some sources of individual variation. Prog Brain Res 1989; 79:289-302.
29. Dani JA, Ji D, Zhou FM. Synaptic plasticity and nicotine addiction. Neuron 2001; 31(3):349-352.
30. Dani JA, Radcliffe KA, Pidoplichko VI. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 2000; 393(1-3):31-38.
31. Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996; 72(1):51-81.
32. Henningfield JE. Understanding nicotine addiction and physical withdrawal process. J Am Dent Assoc 1990; Suppl:2S-6S.
33. Williams JS. The neurobehavioral legacy of prenatal tobacco exposure. NIDA Notes 18[6], 8. 2003.
34. DSM-IV-TR. Barcelona: Masson, 2003.
35. Clasificación de los Trastornos Mentales y del Comportamiento CIE-10. Madrid: Editorial Médica Panamericana, 2000.
36. Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. Am J Psychiatry 1996; 153(10 Suppl):1-31.
37. Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. Am J Psychiatry 1996; 153(10 Suppl):1-31.
38. Leshner AI. Understanding and treating drug abuse and addiction. Bus Health 2001; 19(7):23, 27-23, 30.
39. Leshner AI. Understanding and treating drug abuse and addiction. Bus Health 2001; 19(7):23, 27-23, 30.
40. Nisell M, Nomikos GG, Svensson TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 1995; 76 (3):157-162.
41. Stolerman IP, Mirza NR, Shoaib M. Nicotine psychopharmacology: addiction, cognition and neuroadaptation. Med Res Rev 1995; 15(1):47-72.
42. Moxham J. Nicotine addiction. BMJ 2000; 320(7232):391-392.
43. Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. Am J Psychiatry 1996; 153(10 Suppl):1-31.